468,000 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Acquired by Armistice Capital LLC

Key Points

• Armistice Capital LLC has taken a new position in Centessa Pharmaceuticals, acquiring 468,000 shares valued at approximately $6.73 million, representing about 0.35% ownership of the company.
• Several hedge funds have adjusted their stakes in Centessa Pharmaceuticals, with 82.01% of the stock now owned by institutional investors, indicating strong interest from the sector.
• Centessa Pharmaceuticals saw a decline in its stock rating, with Wall Street Zen downgrading it from "hold" to "sell," while other analysts have maintained a "buy" rating with a price target averaging $31.50.

Armistice Capital LLC bought a new stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 468,000 shares of the company's stock, valued at approximately $6,730,000. Armistice Capital LLC owned approximately 0.35% of Centessa Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in CNTA. GF Fund Management CO. LTD. acquired a new position in shares of Centessa Pharmaceuticals during the fourth quarter worth $31,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Centessa Pharmaceuticals by 15,209.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock worth $46,000 after purchasing an additional 3,194 shares during the period. Osterweis Capital Management Inc. acquired a new position in shares of Centessa Pharmaceuticals during the first quarter worth $47,000. Barclays PLC lifted its holdings in shares of Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after purchasing an additional 4,952 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in shares of Centessa Pharmaceuticals during the first quarter worth $147,000. Institutional investors and hedge funds own 82.01% of the company's stock.

Centessa Pharmaceuticals Stock Down 0.8%

CNTA traded down $0.12 during midday trading on Thursday, hitting $15.79. The company had a trading volume of 897,694 shares, compared to its average volume of 972,106. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $9.60 and a 52 week high of $19.09. The company has a quick ratio of 10.12, a current ratio of 10.11 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $2.11 billion, a price-to-earnings ratio of -8.82 and a beta of 1.47. The stock's 50 day moving average price is $15.88 and its 200 day moving average price is $14.47.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03). On average, research analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Needham & Company LLC assumed coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, May 28th. They set a "buy" rating and a $35.00 price target on the stock. Lifesci Capital raised shares of Centessa Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday. Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a research note on Friday, August 29th. They set an "outperform" rating and a $40.00 target price for the company. Truist Financial started coverage on shares of Centessa Pharmaceuticals in a research note on Monday, July 21st. They set a "buy" rating and a $30.00 target price for the company. Finally, Wells Fargo & Company started coverage on shares of Centessa Pharmaceuticals in a research note on Wednesday. They set an "overweight" rating and a $31.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $31.45.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Mario Alberto Accardi sold 15,000 shares of the business's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $14.00, for a total value of $210,000.00. Following the transaction, the insider directly owned 216,485 shares in the company, valued at $3,030,790. The trade was a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gregory M. Weinhoff sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, June 25th. The shares were sold at an average price of $13.86, for a total transaction of $138,600.00. Following the sale, the insider owned 122,279 shares in the company, valued at $1,694,786.94. The trade was a 7.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 171,322 shares of company stock valued at $2,472,814 in the last three months. Insiders own 7.09% of the company's stock.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.